Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved respons...
Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics
About this item
Full title
Author / Creator
Gao, Yang , Kabotyanski, Elena B , Villegas, Elizabeth , Shepherd, Jonathan H , Acosta, Deanna , Clark Hamor , Sun, Tingting , Montemayor-Garcia, Celina , He, Xiaping , Dobrolecki, Lacey E , Westbrook, Thomas F , Lewis, Michael T , Hilsenbeck, Susan G , Zhang, Xiang H-F , Perou, Charles M and Rosen, Jeffrey M
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Journal title
Language
English
Formats
Publication information
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Subjects
More information
Scope and Contents
Contents
Polo-like kinase (PLK) family members play important roles in cell cycle regulation. The founding member PLK1 is oncogenic and preclinically validated as a cancer therapeutic target. Paradoxically, PLK2 (chromosome 5q11.2) is frequently deleted in human breast cancers, preferentially in basal-like and triple-negative breast cancer subtypes. Here, w...
Alternative Titles
Full title
Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2541569227
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2541569227
Other Identifiers
E-ISSN
2692-8205
DOI
10.1101/2021.06.16.448722
How to access this item
https://www.proquest.com/docview/2541569227?pq-origsite=primo&accountid=13902
